RANKINGS

POPULAR STOCKS

Boundless Bio, Inc.

NasdaqGS:BOLD

Location

United States

Market Cap

USD 23.50 M

Share Price

USD 1.05

Avg Daily Volume

74,090

Change (1 day)

-3.67%

Change (1 year)

Change (YTD)

-52.70%

Boundless Bio, Inc. Price to Earnings Ratio (P/E) on June 13, 2025: -0.36

Boundless Bio, Inc. Price to Earnings Ratio (P/E) is -0.36 on June 13, 2025. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Boundless Bio, Inc. 52-week low Price to Earnings Ratio (P/E) is -0.33 on June 13, 2025, which is 7.83% above the current Price to Earnings Ratio (P/E).
  • Boundless Bio, Inc. 52-week low Price to Earnings Ratio (P/E) is -0.81 on June 13, 2025, which is -127.36% below the current Price to Earnings Ratio (P/E).
  • Boundless Bio, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -0.52.
Key data
Date Price to Earnings Ratio (P/E) Price to Book Ratio (P/B) Price to Sales Ratio (P/S) Enterprise Value to EBITDA (EV/EBITDA)
Market news
NasdaqGS: BOLD

Boundless Bio, Inc.

CEO Mr. Zachary Hornby
IPO Date July 20, 2016
Location United States
Headquarters 9880 Campus Point Drive
Employees 64
Sector 🏥 Health Care
Industries
Biotechnology
🔬 Clinical Trials
💊 Pharmaceuticals
Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

StockViz Staff

June 16, 2025

Any question? Send us an email